The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer

Hui Yang; Kunlun Wang; Tao Wang; Mengxi Li; Bingxu Li; Shenglei Li; Ling Yuan

doi:10.3389/fonc.2020.00300

The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer

Front Oncol. 2020 Mar 5:10:300. doi: 10.3389/fonc.2020.00300. eCollection 2020.

Authors

Hui Yang¹, Kunlun Wang¹, Tao Wang¹, Mengxi Li¹, Bingxu Li¹, Shenglei Li¹, Ling Yuan¹

Affiliation

¹ Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.

Abstract

Esophageal cancer (EC) is one of the most common cancers with poor survival in the world. Nowadays, a generous number of clinical trials are underway on the use of immunotherapy in EC patients, especially the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors. However, only a few patients could benefit from single-agent therapy. Others need combination therapies to enhance the response rate and survival. In this review, we focus on PD-1/PD-L1 inhibitors and its combination options in EC patients. We also summarized the potential predictive biomarkers for PD-1/PD-L1 inhibitors treatment.

Keywords: combination therapy; esophageal cancer; predictive biomarkers; programmed death-1; programmed death-ligand 1.

Publication types

Review